| Pembrolizumab for the treatment of non–small-cell lung cancer EB Garon, NA Rizvi, R Hui, N Leighl, AS Balmanoukian, JP Eder, ... New England Journal of Medicine 372 (21), 2018-2028, 2015 | 6713 | 2015 |
| Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer L Gandhi, D Rodríguez-Abreu, S Gadgeel, E Esteban, E Felip, ... New England journal of medicine 378 (22), 2078-2092, 2018 | 6151 | 2018 |
| Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer EL Kwak, YJ Bang, DR Camidge, AT Shaw, B Solomon, RG Maki, SHI Ou, ... New England Journal of Medicine 363 (18), 1693-1703, 2010 | 5491 | 2010 |
| Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study DR Camidge, YJ Bang, EL Kwak, AJ Iafrate, M Varella-Garcia, SB Fox, ... The lancet oncology 13 (10), 1011-1019, 2012 | 1556 | 2012 |
| Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study CJ Langer, SM Gadgeel, H Borghaei, VA Papadimitrakopoulou, A Patnaik, ... The lancet oncology 17 (11), 1497-1508, 2016 | 1521 | 2016 |
| Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints S Koyama, EA Akbay, YY Li, GS Herter-Sprie, KA Buczkowski, ... Nature communications 7 (1), 10501, 2016 | 1506 | 2016 |
| Overall survival and long-term safety of nivolumab (anti–programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non–small-cell lung cancer SN Gettinger, L Horn, L Gandhi, DR Spigel, SJ Antonia, NA Rizvi, ... Journal of clinical oncology 33 (18), 2004-2012, 2015 | 1325 | 2015 |
| PKC-θ is required for TCR-induced NF-κB activation in mature but not immature T lymphocytes Z Sun, CW Arendt, W Ellmeier, EM Schaeffer, MJ Sunshine, L Gandhi, ... Nature 404 (6776), 402-407, 2000 | 1148 | 2000 |
| PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib JA Engelman, K Zejnullahu, CM Gale, E Lifshits, AJ Gonzales, ... Cancer research 67 (24), 11924-11932, 2007 | 843 | 2007 |
| Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG … SM Gadgeel, L Gandhi, GJ Riely, AA Chiappori, HL West, MC Azada, ... The Lancet Oncology 15 (10), 1119-1128, 2014 | 800 | 2014 |
| Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immuno-Oncology … S Hendry, R Salgado, T Gevaert, PA Russell, T John, B Thapa, M Christie, ... Advances in anatomic pathology 24 (6), 311-335, 2017 | 758 | 2017 |
| Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial AT Shaw, L Gandhi, S Gadgeel, GJ Riely, J Cetnar, H West, DR Camidge, ... The lancet oncology 17 (2), 234-242, 2016 | 716 | 2016 |
| Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non–small cell lung cancer, and other solid tumors A Patnaik, LS Rosen, SM Tolaney, AW Tolcher, JW Goldman, L Gandhi, ... Cancer discovery 6 (7), 740-753, 2016 | 701 | 2016 |
| Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immunooncology … S Hendry, R Salgado, T Gevaert, PA Russell, T John, B Thapa, M Christie, ... Advances in anatomic pathology 24 (5), 235-251, 2017 | 676 | 2017 |
| Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors L Gandhi, DR Camidge, M Ribeiro de Oliveira, P Bonomi, D Gandara, ... Journal of clinical oncology 29 (7), 909-916, 2011 | 668 | 2011 |
| Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer CM Rudin, CL Hann, EB Garon, M Ribeiro de Oliveira, PD Bonomi, ... Clinical Cancer Research 18 (11), 3163-3169, 2012 | 628 | 2012 |
| Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine EM Van Allen, N Wagle, P Stojanov, DL Perrin, K Cibulskis, S Marlow, ... Nature medicine 20 (6), 682-688, 2014 | 575 | 2014 |
| Small cell lung cancer GP Kalemkerian, W Akerley, P Bogner, H Borghaei, LQM Chow, ... Journal of the National Comprehensive Cancer Network 11 (1), 78-98, 2013 | 491 | 2013 |
| Bias-corrected targeted next-generation sequencing for rapid, multiplexed detection of actionable alterations in cell-free DNA from advanced lung cancer patients CP Paweletz, AG Sacher, CK Raymond, RS Alden, A O'Connell, SL Mach, ... Clinical Cancer Research 22 (4), 915-922, 2016 | 316 | 2016 |
| Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib N Wagle, BC Grabiner, EM Van Allen, E Hodis, S Jacobus, JG Supko, ... Cancer discovery 4 (5), 546-553, 2014 | 302 | 2014 |
